153 related articles for article (PubMed ID: 28723928)
1. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
2. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response.
Korpela SP; Hinz TK; Oweida A; Kim J; Calhoun J; Ferris R; Nemenoff RA; Karam SD; Clambey ET; Heasley LE
J Transl Med; 2021 Jan; 19(1):43. PubMed ID: 33485341
[TBL] [Abstract][Full Text] [Related]
3. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
[TBL] [Abstract][Full Text] [Related]
4. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
Iida M; McDaniel NK; Kostecki KL; Welke NB; Kranjac CA; Liu P; Longhurst C; Bruce JY; Hong S; Salgia R; Wheeler DL
BMC Cancer; 2022 Apr; 22(1):447. PubMed ID: 35461210
[TBL] [Abstract][Full Text] [Related]
5. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
6. HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
Meister KS; Godse NR; Khan NI; Hedberg ML; Kemp C; Kulkarni S; Alvarado D; LaVallee T; Kim S; Grandis JR; Duvvuri U
Sci Rep; 2019 Jun; 9(1):9130. PubMed ID: 31235758
[TBL] [Abstract][Full Text] [Related]
7. Spheroid Culture of Head and Neck Cancer Cells Reveals an Important Role of EGFR Signalling in Anchorage Independent Survival.
Braunholz D; Saki M; Niehr F; Öztürk M; Borràs Puértolas B; Konschak R; Budach V; Tinhofer I
PLoS One; 2016; 11(9):e0163149. PubMed ID: 27643613
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models.
Stegeman H; Kaanders JH; van der Kogel AJ; Iida M; Wheeler DL; Span PN; Bussink J
Radiother Oncol; 2013 Mar; 106(3):383-9. PubMed ID: 23453541
[TBL] [Abstract][Full Text] [Related]
9. SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs.
Li WJ; Xie CY; Zhu X; Tang J; Wang L; Lou LG
Acta Pharmacol Sin; 2024 Apr; 45(4):857-866. PubMed ID: 38200149
[TBL] [Abstract][Full Text] [Related]
10. miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC.
Citron F; Segatto I; Musco L; Pellarin I; Rampioni Vinciguerra GL; Franchin G; Fanetti G; Miccichè F; Giacomarra V; Lupato V; Favero A; Concina I; Srinivasan S; Avanzo M; Castiglioni I; Barzan L; Sulfaro S; Petrone G; Viale A; Draetta GF; Vecchione A; Belletti B; Baldassarre G
EMBO Mol Med; 2021 Jul; 13(7):e12872. PubMed ID: 34062049
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines.
Gomes INF; da Silva-Oliveira RJ; da Silva LS; Martinho O; Evangelista AF; van Helvoort Lengert A; Leal LF; Silva VAO; Dos Santos SP; Nascimento FC; Lopes Carvalho A; Reis RM
Cells; 2022 Jan; 11(1):. PubMed ID: 35011716
[TBL] [Abstract][Full Text] [Related]
12. BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth.
Boreddy SR; Nair R; Pandey PK; Kuriakose A; Marigowda SB; Dey C; Banerjee A; Kulkarni H; Sagar M; Krishn SR; Rao S; Ar M; Tiwari V; Alke B; Mv PK; Shri M; Dhamne C; Patel S; Sharma P; Periyasamy S; Bhatnagar J; Kuriakose MA; Reddy RB; Suresh A; Sreenivas S; Govindappa N; Moole PR; Bughani U; Tan SL; Nair P
Cancer Res; 2023 Jun; 83(11):1883-1904. PubMed ID: 37074042
[TBL] [Abstract][Full Text] [Related]
13. Ligand-Independent EGFR Activation by Anchorage-Stimulated Src Promotes Cancer Cell Proliferation and Cetuximab Resistance via ErbB3 Phosphorylation.
Nozaki M; Yasui H; Ohnishi Y
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31615015
[TBL] [Abstract][Full Text] [Related]
14. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.
Gaborit N; Lindzen M; Yarden Y
Hum Vaccin Immunother; 2016 Mar; 12(3):576-92. PubMed ID: 26529100
[TBL] [Abstract][Full Text] [Related]
15. Phytochemicals targeting epidermal growth factor receptor (EGFR) for the prevention and treatment of HNSCC: A review.
Li S; Sun Y
Medicine (Baltimore); 2023 Oct; 102(40):e34439. PubMed ID: 37800790
[TBL] [Abstract][Full Text] [Related]
16. Neuronal-epithelial cross-talk drives acinar specification via NRG1-ERBB3-mTORC2 signaling.
May AJ; Mattingly AJ; Gaylord EA; Griffin N; Sudiwala S; Cruz-Pacheco N; Emmerson E; Mohabbat S; Nathan S; Sinada H; Lombaert IMA; Knox SM
Dev Cell; 2022 Nov; 57(22):2550-2565.e5. PubMed ID: 36413949
[TBL] [Abstract][Full Text] [Related]
17. Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization.
Magi S; Iwamoto K; Yumoto N; Hiroshima M; Nagashima T; Ohki R; Garcia-Munoz A; Volinsky N; Von Kriegsheim A; Sako Y; Takahashi K; Kimura S; Kholodenko BN; Okada-Hatakeyama M
J Biol Chem; 2018 Feb; 293(6):2206-2218. PubMed ID: 29233889
[TBL] [Abstract][Full Text] [Related]
18. A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.
Espinosa-Cotton M; Fertig EJ; Stabile LP; Gaither-Davis A; Bauman JE; Schmitz S; Gibson-Corley KN; Cheng Y; Jensen IJ; Badovinac VP; Laux D; Simons AL
Biomark Res; 2019; 7():14. PubMed ID: 31346466
[TBL] [Abstract][Full Text] [Related]
19. Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer.
Park J; Sarode VR; Euhus D; Kittler R; Scherer PE
Proc Natl Acad Sci U S A; 2012 Dec; 109(51):21058-63. PubMed ID: 23213231
[TBL] [Abstract][Full Text] [Related]
20. Unveiling the role of MGMT and DAPK hypermethylation in response to anti-EGFR agents: Molecular insights for advancing HNSCC treatment.
Arantes LMRB; Silva-Oliveira RJ; de Carvalho AC; Melendez ME; Sorroche BP; de Jesus Teixeira R; Tostes K; Palmero EI; Reis RM; Carvalho AL
Head Neck; 2024 Mar; 46(3):461-472. PubMed ID: 38095042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
